<li id="4w4yg"></li>
<button id="4w4yg"><input id="4w4yg"></input></button>
<li id="4w4yg"></li>
  • <li id="4w4yg"><source id="4w4yg"></source></li>
  • <strike id="4w4yg"></strike>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike><button id="4w4yg"><dl id="4w4yg"></dl></button>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike>
    <bdo id="4w4yg"></bdo>
    產品展示 / products 您的位置:網站首頁 > 產品展示 > 細胞庫 > 細胞系 > 人肺鱗癌細胞SK-MES-1
    人肺鱗癌細胞SK-MES-1

    人肺鱗癌細胞SK-MES-1

    簡要描述:青旗(上海)生物技術發展有限公司,總部位于上海浦東新區,依托本地高校資源,逐步發展成為以生物技術為主的研發、生產、培訓為一體的綜合化產業平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫學科研用戶提供更優質的服務!

    更新時間:2021-05-21

    廠商性質:生產廠家

    瀏覽次數:695

    詳情介紹
    品牌其他品牌貨號BFN60800660
    規格T25培養瓶x1 1.5ml凍存管x2供貨周期現貨
    主要用途僅供科研應用領域醫療衛生,生物產業

    細胞名稱

    人肺鱗癌細SK-MES-1                  

    img1

    貨物編碼

    BFN60800660

    產品規格

    T25培養x1

    1.5ml凍存x2

    細胞數量

    1x10^6

    1x10^6

    保存溫度

    37

    -198

    運輸方式

    常溫保溫運輸

    干冰運輸

    安全等級

    1

    用途限制

    僅供科研用途                1類

     

    培養體系

    DMEM高糖培養基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

    培養溫度

    37

    二氧化碳濃度

    5%

    簡介

    人肺鱗癌細SK-MES-1細胞源于一65歲患有肺鱗狀細胞癌的白人男性,自轉移性胸腔積液分離而來。由青旗(上海)生物技術發展有限公司2018年引種ATCCHTB-58)

    注釋

    Part of: Cancer Cell Line Encyclopedia (CCLE) project.

    Part of: COSMIC cell lines project.

    Part of: MD Anderson Cell Lines Project.

    From: Memorial Sloan Kettering Cancer Center; New York; USA.

    Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2009-091.

    Doubling time: ~50 hours (DSMZ).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Deep exome analysis.

    Omics: Deep RNAseq analysis.

    Omics: DNA methylation analysis.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis.

    STR信息

    AmelogeninXY;CSF1PO12D13S31711;D16S53913;D18S5117D19S43314;D21S1129,30;D2S133819;D3S135816D5S81811;D7S8208;D8S117913,14;FGA2024;TH016,9.3;TPOX8vWA14;

    參考文獻

    DOI=10.1007/978-1-4757-1647-4_5

    Fogh J., Trempe G.L.

    New human tumor cell lines.

    (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

     

    PubMed=833871; DOI=10.1093/jnci/58.2.209

    Fogh J., Wright W.C., Loveless J.D.

    Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

    J. Natl. Cancer Inst. 58:209-214(1977)

     

    PubMed=6935474; DOI=10.1093/jnci/66.2.239

    Wright W.C., Daniels W.P., Fogh J.

    Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

    J. Natl. Cancer Inst. 66:239-247(1981)

     

    PubMed=7017212; DOI=10.1093/jnci/66.6.1003

    Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

    HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

    J. Natl. Cancer Inst. 66:1003-1012(1981)

     

    PubMed=2990217

    Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

    Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

    Am. J. Pathol. 119:361-366(1985)

     

    PubMed=4005855

    Kyoizumi S., Akiyama M., Kouno N., Kobuke K., Hakoda M., Jones S.L., Yamakido M.

    Monoclonal antibodies to human squamous cell carcinoma of the lung and their application to tumor diagnosis.

    Cancer Res. 45:3274-3281(1985)

     

    PubMed=3518877; DOI=10.3109/07357908609038260

    Fogh J.

    Human tumor lines for cancer research.

    Cancer Invest. 4:157-184(1986)

     

    PubMed=3335022

    Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

    Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

    Cancer Res. 48:589-601(1988)

     

    PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x

    Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R.

    Alterations of integrin expression in human lung cancer.

    Jpn. J. Cancer Res. 84:168-174(1993)

     

    PubMed=7736387; DOI=10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q

    Campling B.G., Sarda I.R., Baer K.A., Pang S.C., Baker H.M., Lofters W.S., Flynn T.G.

    Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

    Cancer 75:2442-2451(1995)

     

    PubMed=12794755; DOI=10.1002/ijc.11184

    Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.

    RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

    Int. J. Cancer 106:45-51(2003)

     

    PubMed=14581340

    Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

    TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

    Clin. Cancer Res. 9:4705-4713(2003)

     

    PubMed=15746151; DOI=10.1093/hmg/ddi092

    Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.

    Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

    Hum. Mol. Genet. 14:997-1007(2005)

     

    PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

    Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

    Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

    Cell 131:1190-1203(2007)

     

    PubMed=19472407; DOI=10.1002/humu.21028

    Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

    A gene-alteration profile of human lung cancer cell lines.

    Hum. Mutat. 30:1199-1206(2009)

     

    PubMed=20164919; DOI=10.1038/nature08768

    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

    Cancer Res. 70:2158-2164(2010)

     

    PubMed=22460905; DOI=10.1038/nature11003

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=24002593; DOI=10.1038/bjc.2013.452

    Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.

    Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.

    Br. J. Cancer 109:1599-1608(2013)

     

    PubMed=25485619; DOI=10.1038/nbt.3080

    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

    A comprehensive transcriptional portrait of human cancer cell lines.

    Nat. Biotechnol. 33:306-312(2015)

     

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

    A landscape of pharmacogenomic interactions in cancer.

    Cell 166:740-754(2016)

     

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

    Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

    Characterization of human cancer cell lines by reverse-phase protein arrays.

    Cancer Cell 31:225-239(2017)

     

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

    Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

    Cancer Res. 79:1263-1273(2019)

     

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3

    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

    Next-generation characterization of the Cancer Cell Line Encyclopedia.

    Nature 569:503-508(2019)

    驗收細胞注意事 

    1、收到人肺鱗癌細SK-MES-1,請查看瓶子是否有破裂,培養基是否漏出,是否渾濁,如有請盡快聯系。 

    2、收到人肺鱗癌細SK-MES-1 ,如包裝完好,請在顯微鏡下觀察細胞。,由于運輸過程中的問題,細胞培養瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現細胞懸浮的情況,出現此狀態時,請不要打開細胞培養瓶,應立即將培養瓶置于細胞培養箱里靜 3-5 小時左右,讓細胞先穩定下,再于顯微鏡下觀察,此時多數細胞會重新貼附于瓶壁。如細胞仍不能貼壁,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。 

    3、收到人肺鱗癌細SK-MES-1后,請鏡下觀察細胞,用恰當方式處理細胞。若懸浮的細胞較多,請離心收集細胞,接種到一個新的培養瓶中。棄掉原液,使用新鮮配制的培養基,使用進口胎牛血清。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養。若細胞迏 80% ,血清濃度還是 10。 

    4、收到人肺鱗癌細SK-MES-1時如無異常情 ,請在顯微鏡下觀察細胞密度,如為貼壁細胞,未超80%匯合度時,將培養瓶中培養基吸出,留 5-10ML 培養基繼續培養:超 80%匯合度時,請按細胞培養條件傳代培養。如為懸浮細胞,吸出培養液,1000 /分鐘離 3 分鐘,吸出上清,管底細胞用新鮮培養基懸浮細胞后移回培養瓶。 

    5、將培養瓶置 37培養箱中培養,蓋子微微擰松。吸出的培養基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需。 

    624 小時后,細胞形態已恢復并貼滿瓶壁,即可傳代。(貼壁細胞)將培養瓶里的培養基倒去, 3-5ml(以能覆蓋細胞生長面為準PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細胞為準,一 1-3 分鐘,不超 5 分鐘。可以放37培養箱消化。輕輕晃動瓶壁,見細胞脫落下來,加 3-5ml 培養基終止消化。用移液管輕輕吹打瓶壁上的細胞,使之*脫落,然后將溶液吸入離心管內離心,1000rpm/5min。棄上清,視細胞數量決定分瓶數,一般一傳二,如細胞量多可一傳三,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,以具體細胞和經驗為準。(懸浮細胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可 

    7、貼壁細 ,懸浮細胞。嚴格無菌操作。換液時,換新的細胞培養瓶和換新鮮的培養液37,5%CO2 培養。

     

    特別提醒 原瓶中培養基不宜繼續使用,請更換新鮮培養基培養。

     青旗(上海)生物技術發展有限公司,總部位于上海浦東新區,依托本地高校資源,逐步發展成為以生物技術為主的研發、生產、培訓為一體的綜合化產業平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫學科研用戶提供更優質的服務!

     

     



    留言框

    • 產品:

    • 您的單位:

    • 您的姓名:

    • 聯系電話:

    • 常用郵箱:

    • 省份:

    • 詳細地址:

    • 補充說明:

    • 驗證碼:

      請輸入計算結果(填寫阿拉伯數字),如:三加四=7




    亚洲中文精品久久久久久不卡| 国产成人午夜无码电影在线观看| 无码丰满少妇2在线观看| 日韩AV无码不卡网站| 无码人妻丰满熟妇区96| 成人午夜福利免费专区无码| 久久精品一区二区三区中文字幕| 无码人妻丰满熟妇区免费| 亚洲最大激情中文字幕| 亚洲AV永久青草无码精品| 人妻中文字幕无码专区| 国产做无码视频在线观看浪潮| 日本中文字幕在线不卡高清| 国产V片在线播放免费无码| 在线中文字幕精品第5页| 免费VA在线观看无码| 中文字幕av无码专区第一页| 亚洲中文久久精品无码| 国产精品无码一区二区在线观一| 精品人妻V?出轨中文字幕| 午夜无码视频一区二区三区| 亚洲精品无码久久一线| 最新中文字幕在线| 中文字幕专区高清在线观看| 人妻丰满av无码中文字幕| 在线中文字幕精品第5页| 欧美人妻aⅴ中文字幕| yy111111电影院少妇影院无码| 暴力强奷在线播放无码| 中文字幕一区二区三区在线观看 | 亚洲AV无码久久| 中文字幕免费在线观看| 亚洲一级特黄无码片| 精品久久久久久久无码| 中文字幕av无码一区二区三区电影 | 久久受www免费人成_看片中文| 国产精品无码A∨精品影院| 国产成人无码av| 中文字幕无码高清晰 | 久久影院午夜理论片无码| 日韩免费人妻AV无码专区蜜桃|